Eptinezumab 300 mg N = 128 | |
---|---|
Demographics | |
Mean (SD) age, years | 41.5 (11.33) |
Sex, n (%) | |
Male | 19 (14.8) |
Female | 109 (85.2) |
Ethnicity, n (%) | |
Hispanic or Latino | 26 (20.3) |
Not Hispanic or Latino | 102 (79.7) |
Race, n (%) | |
White | 122 (95.3) |
Black or African American | 4 (3.1) |
Asian | 1 (<1) |
Multiple Races | 1 (<1) |
Clinical characteristics | |
Mean (SD) weight, kg | 77.8 (16.97) |
Mean (SD) height, cm | 166.3 (9.01) |
Mean (SD) BMI, kg/m2 | 28.0 (5.07) |
Migraine history | |
Mean (SD) age at migraine diagnosis, years | 20.4 (8.94) |
Mean (SD) duration of migraine diagnosis, years | 21.2 (11.65) |
Mean (SD) number of years with CM | 13.5 (11.11) |
MOH diagnosis, n (%) | 49 (38.3) |
Mean (SD) number of headache daysa | 20.3 (3.68) |
Mean (SD) number of migraine daysa | 14.1 (4.25) |
Mean (SD) number of migraine attacksa | 10.5 (4.29) |
Most bothersome symptom, n (%)b | |
Sensitivity to light | 31 (24.2) |
Pain | 21 (16.4) |
Nausea/vomiting | 17 (13.3) |
Pain – with activity | 11 (8.6) |
Sensitivity to sound | 11 (8.6) |
Throbbing/pulsation | 8 (6.3) |
Headache | 4 (3.1) |
Vision impacts | 4 (3.1) |
Cognitive disruption | 5 (3.9) |
Multiple | 3 (2.3) |
Pain – anatomical | 3 (2.3) |
Aura | 2 (1.6) |
Dizziness | 2 (1.6) |
Mood changes | 2 (1.6) |
Allodynia | 1 (<1) |
Eye pain | 1 (<1) |
Neck pain | 1 (<1) |
Speech difficulty | 1 (<1) |
Concomitant headache medicationsc | |
Used ≥1 acute headache medication, n (%) | 127 (99.2) |
Thomapyrin N | 57 (44.5) |
Ibuprofen | 52 (40.6) |
Sumatriptan | 43 (33.6) |
Paracetamol | 26 (20.3) |
Naproxen sodium | 13 (10.2) |
Used ≥1 prophylactic medication, n (%) | 46 (35.9) |
Topiramate | 16 (12.5) |